CA3164445A1 - Intranasal pharmaceutical compositions of cgrp inhibitors - Google Patents

Intranasal pharmaceutical compositions of cgrp inhibitors

Info

Publication number
CA3164445A1
CA3164445A1 CA3164445A CA3164445A CA3164445A1 CA 3164445 A1 CA3164445 A1 CA 3164445A1 CA 3164445 A CA3164445 A CA 3164445A CA 3164445 A CA3164445 A CA 3164445A CA 3164445 A1 CA3164445 A1 CA 3164445A1
Authority
CA
Canada
Prior art keywords
cgrp
inhibitor
pain
zavegepant
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3164445A
Other languages
English (en)
French (fr)
Inventor
Vladimir Coric
Charles M. CONWAY
Robert CROOP
Rajesh Kumar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ireland Pharmaceuticals
Original Assignee
Biohaven Pharmaceutical Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Pharmaceutical Holding Co Ltd filed Critical Biohaven Pharmaceutical Holding Co Ltd
Publication of CA3164445A1 publication Critical patent/CA3164445A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
    • A61M11/007—Syringe-type or piston-type sprayers or atomisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0468—Liquids non-physiological

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Mechanical Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3164445A 2019-12-17 2020-12-17 Intranasal pharmaceutical compositions of cgrp inhibitors Pending CA3164445A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962949351P 2019-12-17 2019-12-17
US62/949,351 2019-12-17
PCT/US2020/065452 WO2021127070A1 (en) 2019-12-17 2020-12-17 Intranasal pharmaceutical compositions of cgrp inhibitors

Publications (1)

Publication Number Publication Date
CA3164445A1 true CA3164445A1 (en) 2021-06-24

Family

ID=76478147

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3164445A Pending CA3164445A1 (en) 2019-12-17 2020-12-17 Intranasal pharmaceutical compositions of cgrp inhibitors

Country Status (11)

Country Link
US (1) US20220401439A1 (https=)
EP (1) EP4076395A4 (https=)
JP (1) JP2023507094A (https=)
KR (1) KR20220114613A (https=)
CN (1) CN114980862A (https=)
AU (1) AU2020408705A1 (https=)
BR (1) BR112022011892A2 (https=)
CA (1) CA3164445A1 (https=)
IL (1) IL293647A (https=)
MX (1) MX2022007336A (https=)
WO (1) WO2021127070A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12521389B2 (en) * 2019-06-14 2026-01-13 The Regents Of The University Of California Therapeutic approach to lung disease
WO2022109077A1 (en) * 2020-11-19 2022-05-27 Biohaven Pharmaceutical Holding Company Ltd. Compositions for improved delivery of cgrp inhibitors
JP1706573S (ja) * 2021-02-15 2022-02-01 鼻スプレー器
WO2023064195A1 (en) * 2021-10-11 2023-04-20 Pfizer Ireland Pharmaceuticals Cgrp antagonists for treating trigeminal neuralgia
CN115429882B (zh) * 2022-10-19 2024-08-06 上海交通大学医学院附属第九人民医院 伤害性感觉神经细胞调控药物的用途
CA3252054A1 (en) 2022-11-09 2024-05-16 Tapi Czech Industries S.R.O. SOLID FORMS OF ZAVÉGÉPANT HYDROCHLORIDE AND THEIR PREPARATION PROCESS
CN116003387B (zh) * 2022-11-20 2024-03-26 药康众拓(北京)医药科技有限公司 一种氘代吲唑丙酰胺类化合物、药物组合物和用途
JP1773931S (ja) * 2023-05-17 2024-06-25 鼻スプレー器
CA225743S (fr) * 2023-05-17 2024-09-12 Aptar France Sas Dispositif pour spray nasal
CA225744S (fr) * 2023-05-17 2024-09-12 Aptar France Sas Dispositif pour spray nasal
GB202308123D0 (en) * 2023-05-31 2023-07-12 Orexo Ab New copmosition
CN120733002B (zh) * 2025-09-03 2025-11-25 华中科技大学同济医学院附属同济医院 Cgrp受体小分子拮抗剂在制备治疗嗜酸性慢性鼻窦炎伴鼻息肉的药品中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040076587A1 (en) * 2002-06-19 2004-04-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical composition for intranasal administration containing a CGRP antagonist
US8481546B2 (en) * 2010-03-30 2013-07-09 Bristol-Myers Squibb Company CGRP receptor antagonist
US20160199600A1 (en) * 2013-09-11 2016-07-14 Bixa Research And Health Inc. Single use intranasal atomizer
WO2017001433A1 (en) * 2015-06-29 2017-01-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders
GB201519194D0 (en) * 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
KR102444717B1 (ko) * 2016-04-15 2022-09-16 하. 룬드벡 아크티에셀스카브 인간화 항-pacap 항체 및 그의 용도
CN109476639B (zh) * 2016-07-22 2021-02-26 橘生药品工业股份有限公司 吡咯烷衍生物
US20190135927A1 (en) * 2017-09-29 2019-05-09 Bhl Patent Holdings, Llc Migraine, headache, chronic pain treatment, and prophylaxis options
MX2020009856A (es) * 2018-03-25 2020-10-08 Biohaven Pharm Holding Co Ltd Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp).
AU2020259461A1 (en) * 2019-04-18 2021-11-11 Allergan Sales, Llc CGRP antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo

Also Published As

Publication number Publication date
WO2021127070A1 (en) 2021-06-24
US20220401439A1 (en) 2022-12-22
KR20220114613A (ko) 2022-08-17
EP4076395A1 (en) 2022-10-26
CN114980862A (zh) 2022-08-30
EP4076395A4 (en) 2024-02-07
JP2023507094A (ja) 2023-02-21
BR112022011892A2 (pt) 2022-09-06
IL293647A (en) 2022-08-01
MX2022007336A (es) 2022-09-19
AU2020408705A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
CA3164445A1 (en) Intranasal pharmaceutical compositions of cgrp inhibitors
JP7566889B2 (ja) Ｉｌ－１７ａモジュレーターおよびその使用
CN102781436B (zh) 纤维肌痛综合征的治疗方法
KR102444687B1 (ko) 치환된 디아자헤테로비시클릭 화합물 및 그의 용도
US20240139158A1 (en) Methods of treating pulmonary diseases and disorders
US20180230149A1 (en) Inhibiting the transient receptor potential a1 ion channel
JP4277051B2 (ja) ５−［３−（３−ヒドロキシフェノキシ）アゼチジン−１−イル］−５−メチル−２，２−ジフェニルヘキサンアミド塩酸塩
CN104968656A (zh) 自分泌运动因子抑制剂
CN110638805A (zh) 促进吸烟停止
US9409895B2 (en) Autotaxin inhibitors
US8729073B2 (en) 5-methyl-1-(naphthalen-2-yl)-1H-pyrazole derivatives and their use in potentiating the effect of opioid analgesics
AU2017379247A1 (en) Pharmaceutical dosage forms containing TASK-1 and TASK-3 channel inhibitors, and the use of same in breathing disorder therapy
US20240408080A1 (en) Pharmaceutical compositions of cgrp inhibitors and methods of their use
US20200093737A1 (en) Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
CA3189206A1 (en) Trpv4 inhibitor as therapeutic agent for ocular disease
TW200848035A (en) New combination 627
CN113166051A (zh) 酚类trpv1激动剂的聚乙二醇化前药
US10457644B2 (en) Pyrazol compounds as EAAT3 inhibitors
HK40075170A (en) Intranasal pharmaceutical compositions of cgrp inhibitors
CN102202665A (zh) 包含毒蕈碱性受体拮抗剂和另一种活性成分的药物产品
JP2005060311A (ja) Ｎ−（ベンゾイル）アミノ酸誘導体を有効成分とするニューロパシー性疼痛治療剤
EA048271B1 (ru) Способ получения фармацевтических лекарственных форм, содержащих ингибиторы task-1- и task-3-каналов, и их применение для терапии нарушений дыхания
HK40010023A (en) Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220929

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240802

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241021

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250219

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250219

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250711

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20251112

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260128